, were included in the study. Cases and controls were recruited after obtaining approval from Institutional Ethics Committee and informed consent from participants.
intrOductiOn
Osteoporosis is a well-recognized complication of Cushing's syndrome (CS). It results from an array of systemic and local effects that glucocorticoids have on bone and mineral metabolism. The prevalence of osteoporosis due to endogenous cortisol excess has been reported to be 50-59% [1, 2] and about one-third to half of patients with hypercortisolemia-induced osteoporosis experience fragility fracture. [3] Trabecular bone is more severely affected in CS than cortical bone [4] although some studies do not agree with this. [5] As compared to cortical bone, trabecular bone responds more rapidly to any changes in bone balance, either positive or negative, as bone remodeling takes place at bone surfaces and trabecular bone has greater surface-to-volume ratio. [6] Spinal trabecular bone mineral density (BMD) as measured by quantitative computed tomography was the most severely affected when studied in eugonadal female patients. [7] Most of the studies on BMD in patients with CS are from western countries where the population is vitamin D sufficient. As majority of our population is vitamin D deficient or insufficient, [8, 9, 10] we decided to study bone health in CS patients to evaluate the extent of the problem in this population. Our primary objective was to assess BMD in patients with CS in comparison to controls. We also looked into how BMD differs in different types of endogenous CS.
patients with exogenous CS, and previous history of metabolic bone diseases and systemic diseases such as rheumatoid arthritis, bronchial asthma, or history of intake of antiepileptic drugs that affect bone health.
The patients were carefully assessed using a detailed pro forma including signs and symptoms of CS. Baseline investigations that consisted of serum calcium, phosphate, albumin, creatinine, alkaline phosphatase, 24-h urinary calcium, and 24-h urinary phosphate were measured on Hitachi 917, Roche, Germany. The intra-assay and inter-assay coefficients of variation were 3.5-5.0%. Serum thyroxine (T4), testosterone, cortisol, and dehydroepiandrosterone sulfate (DHEAS) were measured using electro-chemiluminescent immunoassay performed on a Roche, Cobas e411 autoanalyzer. Serum intact parathormone (iPTH), thyrotropin (TSH), leuteinising hormone, follicle stimulating hormone, and plasma adrenocorticotropin (ACTH) were done using electro-chemiluminescent immunometric assay performed on a Roche, Cobas e411 autoanalyzer. 25(OH) vitamin D was done using chemiluminescent immunoassay on the Diasorin LIASON autoanalyzer. X-ray chest postero-anterior view, X-ray of dorso-lumbar (D-L) spine antero-posterior (AP) and lateral view (D4-L5), and X-ray of pelvis AP view as well as BMD were measured in all the patients. X-rays were analyzed by an experienced radiologist and interpreted as presence or absence of fracture. X-rays of D-L spine were interpreted according to Genant's classification. [11] B M D w a s m e a s u r e d b y d u a l -e n e r g y X -r a y absorptiometery (DXA) (Discovery A 84023, Hologic Inc., MA, USA) at lumbar spine (L1-L4, AP) and left hip as per the guidelines of the International Society for Clinical Densitometry (ISCD). [12] The precision was measured by testing BMD three times in 15 study subjects using ISCD precision assessment tool.
[13] The coefficient of variation at lumbar spine and hip was 1.3% and 1.5% with least significant change being 0.046 and 0.038 at spine and hip, respectively. BMD of the patients was recorded in terms of absolute mineral content in g/cm 2 and Z-score at both sites. The biochemical, hormonal (25(OH) vitamin D, iPTH, T4, TSH, and testosterone), and bone densitometry assessment was also done for the control group.
The data are represented as mean ± SD. The differences in the mean values of various parameters including BMD values at both sites between patients with CS and controls were compared using Student's t-test. Serum 25(OH) vitamin D, iPTH, testosterone, and DHEAS were correlated with BMD. Etiology of CS, duration of disease, and degree of hypercortisolemia were also correlated with BMD. P value less than 0.05 was considered significant.
reSuLtS
We included 37 patients with CS (28 females; 16 Cushing's disease [CD], 7 adrenal cause, 6 ectopic ACTH syndrome, and 8 unknown ACTH source) and 48 age-, sex-, and season-matched controls (31 females). We found significantly higher central obesity in CS group compared to controls. Eighty-one percent of CS subjects were hypertensive, whereas none of the controls was hypertensive. The demographic and anthropometric parameters are detailed in Table 1 . Among the patients with CS, proximal muscle weakness was the most common presentation (94.6%) followed by abdominal striae (89%). Easy bruisability, moon face, and facial plethora were the other common findings (each 83.8%). Although 56.7% patients with CS complained of backache, only 8.1% gave positive history of any fracture.
The details of hormonal and biochemical parameters are presented in Table 2 . Serum phosphate was significantly lower in CS, but phosphate creatinine ratio was not statistically different. Serum alkaline phosphatase (SAP) was significantly higher in CS group. However, there was no difference between the two groups in serum levels of vitamin D, iPTH, and testosterone (in males) levels.
BMD (both total LS and hip) as well as Z scores were significantly lower in CS patients as compared to controls [ Table 3 and Figure 1 ]. Neither LS nor hip BMD was significantly different among different etiological groups of CS [ Table 4 ]. The difference in BMD was also not significant between eumenorrhoeic and oligo-/amenorrhoeic patients with CS. We found negative correlation with serum morning cortisol and BMD at both LS (r 2 = 0.09, P = 0.08) and hip (r 2 = 0.09, P = 0.09) though this was not statistically significant [ Figure 2 ].
diScuSSiOn
Our study confirms the fact that patients with CS are at very high risk of osteoporosis. We found significantly lower BMD and Z-scores at both LS and hip in patients with CS compared to controls. Bone loss was more severe in LS (Z score −2.50 ± 1.54) than hip (Z score −1.35 ± 0.98) as hypercortisolemia affects trabecular bone more than cortical bone.
BMD and Z-scores did not vary among different etiologies of CS such as pituitary adenoma, adrenal adenoma/carcinoma, or ectopic ACTH syndrome. In another study [14] too, no difference of BMD in relation to etiology of CS was found. However, few studies have shown that patients with CD maintain better BMD in comparison to patients with adrenal CS due to osteoanabolic effect of DHEAS in ACTH-dependent CS. [15, 16] In our study, the BMD parameters were not significantly different among male or female patients with CS neither did it vary significantly between eumenorrheic and hypo-/amenorrheic females. This is in concordance with other studies [14, 17] which showed that neither gender nor gonadal status significantly related with BMD in CS. Duration of symptoms (r 2 = 0.01, P = 0.53) and age of patients (r 2 = 0.00008, P = 0.95) did not correlate with LS BMD. Similarly, they did not correlate with hip BMD. We found negative correlation with serum morning cortisol and BMD at both LS (r 2 = 0.09, P = 0.08) and hip (r 2 = 0.09, P = 0.09) though this was not statistically significant.
On DXA scan, 44.5% (n = 12, total 27) of patients with CS had osteoporosis and 40.7% (n = 11, total 27) had osteopenia (3 patients did not have BMD and 7 patients were below 20 years of age, so T score not compared). Thirteen (35.1%) patients had radiological evidence of vertebral fracture (wedge deformity 6, biconcave deformity 6, and crush deformity 1). The most common site of vertebral fracture was D10-L2. Eight (21.6%) patients had one or more rib fractures and five patients had bilateral avascular necrosis (AVN) of femoral head (confirmed by magnetic resonance of hip; three with stage 2 and two patients with stage 3 AVN). However, clinical history of fracture and height loss was found only in 8.1% and 16.2% of patients with CS, respectively. This finding clearly suggests that patient with CS should be evaluated for bone health as there may be silent osteopenia and osteoporosis potential to cause significant morbidity and mortality. According to another study, [3] the risk of fracture increased within the last 2 years prior to diagnosis.
There was significantly lower serum phosphate in patients with CS as compared to controls. But when serum phosphate was corrected as phosphate creatinine ratio, the difference was no longer significant. Twenty-four hour urinary calcium and phosphate excretion did not differ significantly between the two groups. However, there was elevated SAP level in CS group as compared to control group. Although we did not measure bone-specific SAP or gamma glutamyl transpeptidase, the two groups did not differ in other liver enzymes such as SGOT and SGPT. This elevated SAP may be because of fracture in CS group. Previous studies have reported significantly low serum phosphate in patients with CS and adrenal incidentaloma [18] in comparison to controls with no difference in 24 h urinary excretion of phosphate.
This could be explained as majority of our population is vitamin D deficient; our patients with CS would also have low vitamin D and consequently secondary hyperparathyroidism, which would cause further bone loss. But we did not find significant difference in serum calcium, 24 h urinary calcium excretion, serum iPTH, and 25(OH) vitamin D between CS patients and healthy controls. However, we did not take into account history of vitamin D intake in study population.
Though this is the first study from Indian subcontinent to look into the bone health parameters in patients with CS, yet the limitations are that the bone turnover markers were not done and quantitative software analysis (e.g. SpineAnalyzer) to evaluate vertebral fracture was not used. Follow-up with parameters pertaining to bone health to see recovery after remission of CS was also not done.
cOncLuSiOn
Patients with CS are at increased risk of having fracture secondary to osteopenia and osteoporosis. Our study has clearly shown that LS BMD in patients with CS is more affected than hip BMD and the decrease in BMD is irrespective of menstrual status, duration, and severity of hypercortisolism and etiology of CS. There is no significant association of vitamin D and iPTH with loss of BMD in patients with CS.
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